Price$17.59+0.52 (+3.08%)
01:30 PM06:45 PM
News · 26 weeks65+120%
2026-02-012026-07-26
Mix2690d
- Other10(38%)
- Insider9(35%)
- SEC Filings4(15%)
- Analyst1(4%)
- Earnings1(4%)
- Leadership1(4%)
Latest news
25 items- PRMiniMed Flex™ Now Available to Medicare and Medicare Advantage BeneficiariesNORTHRIDGE, Calif., July 22, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced that Medicare and Medicare Advantage beneficiaries now have access to the MiniMed Flex™ system with its latest sensor portfolio. This milestone now makes the company's smallest and only app-controlled insulin pump system available to more people living with diabetes. Designed to fit more naturally into everyday life, MiniMed Flex™ helps reduce the daily burden of diabetes management so people can focus more on the moments that matter to them. MiniMed Flex™ is about half the size* of previous MiniMed p
- PRMiniMed to Announce Its Fiscal Year 2027 First Quarter Financial ResultsNORTHRIDGE, Calif., July 20, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced that it expects to report financial results on Tuesday, September 1, 2026, for its first quarter of fiscal year 2027, which ends on Friday, July 31, 2026. A news release containing summary financial information is expected at approximately 3:45 a.m. Pacific Daylight Time (PDT) and will be available at https://news.minimed.com.A webcast discussing results is expected be held from 5:45 to 6:30 a.m. PDT, accessible at https://investors.minimed.com.A replay of the webcast and transcript of the prepared re
- INSIDERSEC Form 3 filed by new insider Endicott David J.3 - MiniMed Group, Inc. (0002062583) (Issuer)
- INSIDERSEC Form 3 filed by new insider Burman Linnea3 - MiniMed Group, Inc. (0002062583) (Issuer)
- INSIDERSVP, Gen. Counsel, Corp. Sec. Wills Courtney Nelson was granted 82,787 shares, increasing direct ownership by 150% to 138,146 units (SEC Form 4)4 - MiniMed Group, Inc. (0002062583) (Issuer)
- INSIDERVP, Chief Accounting Officer Gyurci John was granted 24,244 shares, increasing direct ownership by 154% to 39,941 units (SEC Form 4)4 - MiniMed Group, Inc. (0002062583) (Issuer)
- INSIDERSVP, Chief HR Officer Chandrasena Gillian was granted 44,188 shares, increasing direct ownership by 34% to 174,844 units (SEC Form 4)4 - MiniMed Group, Inc. (0002062583) (Issuer)
- INSIDEREVP, Chief Financial Officer Spooner Chad was granted 116,607 shares, increasing direct ownership by 43% to 386,008 units (SEC Form 4)4 - MiniMed Group, Inc. (0002062583) (Issuer)
- INSIDEROfficer Dianaty Ali was granted 131,312 shares, increasing direct ownership by 68% to 323,170 units (SEC Form 4)4 - MiniMed Group, Inc. (0002062583) (Issuer)
- INSIDERChief Executive Officer Dallara Que was granted 297,618 shares, increasing direct ownership by 48% to 916,099 units (SEC Form 4)4 - MiniMed Group, Inc. (0002062583) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cundy Scott T3 - MiniMed Group, Inc. (0002062583) (Issuer)
- SECSEC Form 10-K filed by MiniMed Group Inc.10-K - MiniMed Group, Inc. (0002062583) (Filer)
- SECMiniMed Group Inc. filed SEC Form 8-K: Leadership Update, Shareholder Director Nominations, Other Events, Financial Statements and Exhibits8-K - MiniMed Group, Inc. (0002062583) (Filer)
- PRMiniMed appoints Alcon CEO David Endicott and Linnea Burman to its Board of DirectorsDavid Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experience; Linnea Burman adds MedTech operating depthNORTHRIDGE, Calif., June 29, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced that David Endicott and Linnea Burman have joined its Board of Directors, effective today, expanding the Board from nine to 11 members. Endicott will serve as a member of the Board's Compensation and Talent Committee. David Endicott, Chief Executive Officer of Alcon, brings global healthcare leadership and public company experienceAs MiniMed bui
- PRMiniMed launches Instinct sensors in Europe giving people with diabetes more sensor choice with the same proven outcomesMiniMed automated insulin delivery and smart MDI systems can now be paired with Instinct and Instinct Go, made by Abbott, the smallest, longest-wear sensors in the company's portfolioNORTHRIDGE, Calif., June 23, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced the commercial launch in Europe of both the MiniMed™ 780G system integrated with the Instinct sensor and the MiniMed Go™ system integrated with the Instinct Go sensor. The Instinct and Instinct Go sensors, made by Abbott, will be rolled out gradually across Europe starting this month, expanding MiniMed's sensor portfolio in the region.
- PRMiniMed's Smallest App-Controlled Insulin Pump is Now Available in the U.S.People with type 1 or insulin-requiring type 2 diabetes in the U.S. can now wear MiniMed's smallest pump, paired with the Simplera Sync™ sensorNORTHRIDGE, Calif., June 17, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), today announced its first commercial launch of the MiniMed Flex™ system in the United States — its first app-controlled pump and the company's smallest insulin pump yet. The system launches with Simplera Sync™ sensor, a disposable, all-in-one sensor with easy two-step insertion. The launch with the Instinct sensor, made by Abbott, will follow later this summer.* For years, people who use insulin pumps have had to
- SECMiniMed Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MiniMed Group, Inc. (0002062583) (Filer)
- PRMiniMed to Expand Sensor Portfolio with Integrated Dual Glucose-Ketone Sensors Made by AbbottAgreement builds on the companies' ongoing partnership to expand choice and simplify diabetes management NORTHRIDGE, Calif., June 3, 2026 /CNW/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced an expanded agreement with Abbott to collaborate on commercializing dual glucose-ketone sensors designed to integrate exclusively with MiniMed smart dosing systems. These new dual monitoring sensors are designed to enable early, real-time detection of rising ketones to help prevent diabetic ketoacidosis (DKA), a life-threatening complication.1 The agreement builds on the companies' existing partnership for
- PRMiniMed Delivers Strong Fourth Quarter and Full Fiscal Year 2026 Financial Results; Provides Fiscal Year 2027 OutlookContinued momentum in Q4, with net sales of $837 million growing 16% as reported and 9% organic year-over-yearRecord annual net sales performance surpasses $3B for first time, growing 14% as reported and 8% organicAdvanced global pipeline ahead of schedule with FDA clearance for MiniMed Flex™, CE Mark for Instinct, and global launch of MiniMed Go™ Smart MDINORTHRIDGE, Calif., June 3, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today reported financial results for its fourth quarter and full fiscal year ended April 24, 2026. "MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets
- PRMiniMed to Showcase MiniMed Flex™ and MiniMed Go™ at the American Diabetes Association Scientific SessionsFollowing this week's launch of MiniMed Go™, MiniMed will bring hands-on demonstrations of the system and new clinical dataNORTHRIDGE, Calif., May 27, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced an overview of its upcoming presence at the American Diabetes Association's (ADA) Scientific Sessions in New Orleans June 5-8. The meeting marks MiniMed's first U.S. diabetes congress since becoming a standalone public company — and the first to feature its newest generation of technology designed to give people with diabetes more freedom every day. At ADA, MiniMed will showcase te
- PRMiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare ConferenceNORTHRIDGE, Calif., May 26, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced that management will participate in a fireside chat at the upcoming Goldman Sachs 47th Annual Global Healthcare Conference. The fireside chat will take place on Monday, June 8, 2026, at 11:20 a.m. EDT.A live webcast and replay will be accessible on the MiniMed Investor Relations website: investors.minimed.com/events.About MiniMedMiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than
- PRNew Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G SystemRandomized crossover trial reinforces SmartGuard™ algorithm as key driver of automated insulin delivery performanceNORTHRIDGE, Calif., May 21, 2026 /PRNewswire/ -- MiniMed (NASDAQ:MMED), a global leader in diabetes technology, today announced results from a new randomized crossover study demonstrating that glycemic outcomes for study participants were virtually identical when using the MiniMed™ 780G system with either the Simplera Sync™ sensor or Instinct sensor, made by Abbott. This data, published today in Diabetes Technology & Therapeutics, reinforces that the automated insulin delivery (AID) algorithm, not the sensor, is the primary determinant of clinical outcomes.1
- SECMiniMed Group Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - MiniMed Group, Inc. (0002062583) (Filer)
- ANALYSTThe Benchmark Company initiated coverage on MiniMed with a new price targetThe Benchmark Company initiated coverage of MiniMed with a rating of Buy and set a new price target of $20.00
- SECSEC Form SCHEDULE 13G filed by MiniMed Group Inc.SCHEDULE 13G - MiniMed Group, Inc. (0002062583) (Subject)
MMED FAQ
6 questionsWhere does MMED stock trade?
MiniMed Group Inc. (MMED) is listed on NASDAQ.What sector and industry is MMED in?
MiniMed Group Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did MiniMed Group Inc. go public?
MiniMed Group Inc. (MMED) completed its IPO in 2026.What are analysts saying about MMED?
MiniMed Group Inc. has had 8 recent analyst actions on file. The most recent action was from The Benchmark Company: Buy with a $2000.00 price target on 2026-05-12. Recent price targets range from $1600.00 to $2700.00.What companies are similar to MMED?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare MMED side-by-side with any of them on Quantisnow.How can I track MMED on Quantisnow?
Quantisnow aggregates MiniMed Group Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MMED to receive live email and push alerts on every new disclosure.